Daily Stock List
Omnitek Engineering Corp. (OMTK)
Marketbeat, FeedBlitz, OTCPicks, and Penny Stock Rumble reported earlier on Innovative Food Holdings, Inc. (OMTK), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Omnitek Engineering Corp. develops and sells proprietary diesel-to-natural gas engine conversion systems and complementary products. This includes new natural gas engines, which use the Company’s technology. These provide its worldwide customers with innovative alternative energy and emissions control solutions that are sustainable and affordable. OTCQB-listed, Omnitek Engineering is based in Vista, California.
The Company’s dedication is to be at the frontline of technology. Moreover, its dedication is to develop cutting-edge solutions, which redefine the future of low emissions, energy independence, and transportation.
Omnitek’s conversion technology provides fleets with a 100 percent dedicated natural gas engine at a fraction of the cost of a new natural gas engine. The strategic alliance provides an assembly-line remanufacturing process providing the benefits of capacity, consistency, and quality.
The Company’s products include New Natural Gas Engines, Engine Specific Diesel-to-Natural Gas (DNG) Engine Conversion Kits, and products for Diesel-to-Natural Gas Engine Conversions, Engine Management System (EMS) and Components, EFI for V-Twin Motorcycles and Small Engines, and Hydrogen Internal Combustion Engines. The DNG system has established Omnitek Engineering as a leader in the industry.
Omnitek has formed a strategic alliance with LKQ Corp. (LKQ) to produce "drop-in" natural gas engines at Omnitek’s facility in Monterrey, Mexico, first for the widely-used Mercedes OM904 and OM906 engines. LKQ is a foremost provider of alternative and specialty parts to repair and accessorize automobiles and other vehicles.
In July 2016, Omnitek Engineering announced that it received international certification for its patented fuel rail technology. This is based on tests conducted by an independent agency and standards sanctioned by the United Nations Economic Commission for Europe, specifically UN ECE R110.
Recently, Omnitek Engineering announced it will participate in a $1.5 million grant study with its partner Olson-Ecologic Testing Laboratories (Fullerton, California). The study is to demonstrate its clean natural gas engine technology for off-road heavy duty construction vehicle applications in the greater Los Angeles, California area.
Omnitek Engineering will develop an 18-liter Caterpillar natural gas engine capable of operating on CNG, LNG, or low-carbon intensive renewable biogas (R-CNG) through employing its patented diesel-to-natural gas engine conversion technology. Olson-Ecologic Engine Testing Laboratories will serve as project manager. Olson-Ecologic will be responsible for rigorous testing at its facility before demonstrations under real-life conditions.
Last week, Omnitek Engineering reported results for its Q4 and year ended December 31, 2016. Revenues for Q4 ended December 31, 2016 were $361,152 versus $313,493 a year earlier.
For Q4, the Company reported a net loss of $193,800, or $0.01 per share, versus $329,696, or $0.02 per share, a year ago. Gross margin for Q4 was $106,539 versus $47,148 the year prior.
Innovative Food Holdings, Inc. (OMTK), closed Monday's trading session at $0.15, down 25.00%, on 26,639 volume with 9 trades. The average volume for the last 60 days is 12,567 and the stock's 52-week low/high is $0.13/$0.51.
eCobalt Solutions, Inc. (ECSIF)
We are reporting on eCobalt Solutions, Inc. (ECSIF) today, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, eCobalt Solutions, Inc. explores for mineral properties in the United States and Canada. The Company’s main asset is the 100 percent owned Idaho Cobalt Project (ICP). This Project remains the sole, advanced stage, near term, environmentally permitted, primary cobalt deposit in the U.S. The Company previously went by the name Formation Metals, Inc. It changed its name to eCobalt Solutions, Inc. in August of 2016. Established in 1988, eCobalt Solutions is based in Vancouver, British Columbia.
The Company’s rebranding accurately reflects the present and future direction of eCobalt Solutions as a strong player in the renewable energy and electric vehicle sectors. eCobalt Solutions’ dedication is to providing a distinct opportunity for consumers to acquire an ethically sourced, environmentally sound, transparent supply of battery grade cobalt salts, secured safely and responsibly in the U.S. Battery grade cobalt salts are vital for the fast-growing rechargeable battery and renewable energy sectors.
eCobalt Solutions’ Idaho Cobalt Project (ICP) consists of the Mine /ill (M&M) site situated in Lemhi County, Idaho, near the town of Salmon, Idaho, and also the Cobalt Production Facility (CPF).
CPF is a stand-alone hydrometallurgical facility expected to be in Southern Idaho. It will process concentrates from the M&M into cobalt, copper, and gold end products. The project is scheduled to produce the equivalent of 1,500 tons of high purity cobalt per year over a projected mine life of 12.5 years.
Commissioning of a Feasibility Study was awarded to Micon International and SNC-Lavalin on June 21, 2016. eCobalt Solutions stated that Micon International was already familiar with the Idaho Cobalt Project (ICP), acting as due diligence engineers for lenders in the 2011 financing. Also, SNC-Lavalin has experience in cobalt hydrometallurgical solvent extraction.
The ICP is fully permitted. It received a final Environmental Impact Statement and positive Records of Decision from the U.S. Department of Agriculture National Forest Service and the U.S. Environmental Protection Agency. A Feasibility Study on the ICP completed in 2008 allowed eCobalt Solutions to finance the initial construction of the project. So far, about 90 percent of the earthworks have been completed at the mine site.
eCobalt Solutions, Inc. (ECSIF), closed Monday's trading session at $0.9315, down 2.46%, on 44,630 volume with 25 trades. The average volume for the last 60 days is 156,270 and the stock's 52-week low/high is $0.1373/$1.14.
Cyalume Technologies Holdings, Inc. (CYLU)
SmallCapVoice and SeriousTraders reported earlier on Cyalume Technologies Holdings, Inc. (CYLU), and we also report on the Company, here at the QualityStocks Daily Newsletter.
Cyalume Technologies Holdings, Inc. manufactures and sells chemiluminescent products, and reflective and photoluminescent materials. The Company sells these products to the military, ammunition, and commercial and public safety markets in the United States and around the world. Cyalume is the sole supplier of chemical light to the U.S. military and other premier organizations globally. The Company lists on the OTC Markets Group’s OTCQB.
Cyalume Technologies has its corporate office in Fort Lauderdale, Florida. It has manufacturing and distribution for chemical light, ammunition, and commercial chemical products, which serve North and South America and Asia, located in West Springfield, Massachusetts.
The Company is the international leader in chemical light solutions. It provides light sticks, chemi-luminescent ammunition, as well as infra-red devices. Additionally, Cyalume is a Food and Drug Administration (FDA) approved manufacturer of API components for the pharmaceutical industry and produces complex long chain polymers utilized in a wide variety of final applications. These range from the F35 Joint Strike Fighter to a coating for implantable medical devices.
Cyalume Technologies’ ChemLight and SnapLight brands have a reputation for brightness and reliability. Pertaining to Industrial applications, Cyalume’s chemical light technologies are used by mining, manufacturing and other industries where a safe and reliable light source is crucial.
The Company provides emergency lights to hospitals, hotels, schools, and other facilities. In addition, it provides ammunition. Cyalume has its Training & Tactical Ammunition. This is the world's first 40 mm non-pyrophoric, non-dud producing training round.
Cyalume Specialty Products, Inc. is headquartered in Bound Brook, New Jersey. This subsidiary manufactures and distributes products for the pharmaceutical, medical products, and cosmetics industry.
Cyalume Specialty Products manufactures products from simple raw ingredients to finished product formulations to complex high performance polymers. It works with customers from product conceptualization and early stage proof of principle to definition and optimization of the full-scale manufacturing process.
The Company’s Cyalume Technologies SAS subsidiary manufactures and distributes for Europe, the Middle East and Africa. This includes varied chemical light products, tactical training equipment and devices, and certain chemical formulations. Cyalume Technologies SAS manufactures and supplies EMEA Military, Safety and Security markets with innovative and dependable lights for military, public security, industrial, commercial and personal use.
Cyalume Technologies Holdings, Inc. (CYLU), closed Monday's trading session at $0.25, down 1.34%, on 34,824 volume with 21 trades. The average volume for the last 60 days is 64,829 and the stock's 52-week low/high is $0.03/$0.395.
Butler National Corp. (BUKS)
Marketbeat and FeedBlitz reported on Butler National Corp. (BUKS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed, Butler National Corp. is a foremost manufacturer and provider of support systems for commercial and military aircraft. In addition, the Company is a recognized provider of management services in different business groups including the gaming industry. Butler operates in the Aerospace and Services business segments.
The Company has its corporate headquarters in Olathe, Kansas. Butler National Corporation formed in 1968 via the merger of an aviation research firm owned by the Butler family and National Connector Corporation. Butler National combined resources of the two companies to develop one of the first commercial Area Navigation System (RNAV) used for airplane navigation.
Butler National’s subsidiaries include Avcon Industries, Inc.; Butler Avionics, Inc.; BCS Design, Inc.; Boot Hill Casino & Resort; The Stables Casino; and Butler National-Tempe. Avcon Industries provides aircraft owners and operators with products and services designed to satisfy special mission requirements, or enhance the utility of business jets and turboprops.
Butler Avionics’ services include new installations and retrofits, to avionics, autopilot, instruments, and radar troubleshooting and repair. BCS Design is a full-service architectural firm.
Boot Hill Casino & Resort is in Dodge City, Kansas. It is home to the first state owned and operated casino gaming in Kansas. The Stables Casino is a Class III gaming establishment in Miami, Oklahoma. It is owned by the Miami Tribe and the Modoc Tribe. Butler National-Tempe operates in the Defense Contracting & Electronics industry.
Butler National’s Aerospace segment concentrates on the manufacturing of support systems for "Classic" commercial and military aircraft. This includes the Butler National TSD for the Boeing 737 and 747 Classic aircraft.
This segment also focuses on switching equipment for Boeing McDonnell Douglas Aircraft, weapon control systems for Boeing Helicopter, and performance enhancement structural modifications for Learjet, Cessna, Dassault and Beechcraft business aircraft. The Company’s Management Services segment includes temporary employee services, gaming services, as well as administrative management services.
In March, Butler National announced its financial results for Q3 fiscal 2017 ended January 31, 2017.
Company management commented that, "The fiscal quarter-ended January 31, 2017 was a successful quarter continuing a positive fiscal year 2017. Revenue increased 2 percent to $11.3 million in the three months ended January 31, 2017, as compared to $11.1 million in the three months ended January 31, 2016. The increase in revenue reflects an increase in Professional Services revenue of 5 percent and a decrease of 3 percent in Aerospace Products revenue. Butler National Corporation continues to drive growth in international markets and through the development of new supplemental type certificates. This includes significant efforts in South America, Europe, Africa, and Asia.”
Butler National Corp. (BUKS), closed Monday's trading session at $0.225, down 9.27%, on 26,435 volume with 9 trades. The average volume for the last 60 days is 14,477 and the stock's 52-week low/high is $0.138/$0.31.
DOCASA, Inc. (DCSA)
We are reporting on DOCASA, Inc./strong> (DCSA) today, here at the QualityStocks Daily Newsletter.
DOCASA, Inc. focuses on investing in the fast-growing specialty coffee market, primarily in the United Kingdom. The Company, by way of its subsidiary, Department of Coffee and Social Affairs Ltd. (London, England) has established and is growing an award-winning, market leading UK specialty coffee shop and online retail business. DOCASA has its corporate headquarters in Schaumburg, Illinois, and the Company’s shares trade on the OTCQB.
DOCASA’S stores sell proprietary coffee and related products, and also complementary food and snacks. In addition, the Company is pursuing franchising and/or licensing of its branded shops and premium product offerings outside of the UK. This is in countries where the premium coffee market is quickly expanding.
Last week, DOCASA, via its award-winning subsidiary, Department of Coffee and Social Affairs Limited announced the securing of its first coffee shop site in Manchester, UK. This new site is on the ground floor of Faulkner House, which is a 25,000-sq. ft. building of serviced offices, in Manchester's Piccadilly Gardens area.
The new site will be the Department of Coffee and Social Affairs' flagship store as well as barista training hub in the northern part of England. Moreover, it will act as a co-work space for professionals, with hot desks, breakout spaces, as well as meeting rooms available to rent by the hour.
Department of Coffee and Social Affairs served its first coffee in December of 2010 at Leather Lane, London. It has subsequently opened many coffee shops across the UK as part of it roll out strategy to become a nationwide specialty coffee enterprise. Department of Coffee and Social Affairs operates in destination sites across London and the UK and no two shops look alike.
Today, DOCASA, via its Department of Coffee and Social Affairs, announced the appointment of Mr. Michael Chuter, FCA, CMIIA. Mr. Chuter will be the Senior Non-Executive Director of Department of Coffee and Social Affairs.
He will have oversight of financial reporting and corporate governance. Mr. Chuter is a Fellow of the United Kingdom's Institute of Chartered Accountants and the Institute of Internal Auditors. He has Board level experience across the public, private, and voluntary sectors.
DOCASA, Inc. (DCSA), closed Monday's trading session at $1.85, down 6.67%, on 74,375 volume with 160 trades. The average volume for the last 60 days is 3,344 and the stock's 52-week low/high is $1.01/$3.00.
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $3.63, off by 0.55%, on 8,175 volume with 30 trades. The stock’s average daily volume over the past 60 days is 11,552, and its 52-week low/high is $1.15/$5.84.
eXp World Holdings Inc., holding company for the Agent-Owned Cloud Brokerage®, this morning reported its financial results for the fourth quarter and full year ended December 31, 2016. Among the highlights, the company recorded a 137 percent year-over-year increase in revenues for the 12-month period, as well as a 397 percent increase in adjusted EBITDA to $1.6 million. EXPI found similar success in promoting the growth of eXp Realty, achieving a 178 percent increase in the number of agent and brokers on the platform during 2016.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
eXp World Holdings, Inc. (OTCQB: EXPI) Reports 137% Revenue Growth in FY16, Record Q4
eXp World Holdings to Present at The MicroCap Conference on April 4th in New York
eXp Realty Reaches 3,000 Agent Milestone
India Globalization Capital, Inc. (IGC)
The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.6003, up 27.72%, on 2,209,426 volume with 3,939 trades. The stock’s average daily volume over the past 60 days is 235,145, and its 52-week low/high is $0.19/$0.6102.
India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.
The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.
The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.
IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.
IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.
Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.
Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer
India Globalization Capital, Inc. Company Blog
India Globalization Capital, Inc. News:
IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders
NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Benzinga Article
IGC Announces Third Quarter Financial Results
GreenStone Healthcare Corp. (GRST)
The QualityStocks Daily Newsletter would like to spotlight GreenStone Healthcare Corp. (GRST). Today, GreenStone Healthcare Corp. closed trading at $0.03803, up 15.24%, on 55,603 volume with 9 trades. The stock’s average daily volume over the past 60 days is 64,844, and its 52-week low/high is $0.015/$0.083.
GreenStone Healthcare Corp. (GRST), through its subsidiaries, offers addiction and mental health rehabilitation treatments for residents, including out-patient counseling, coaching, intervention, psychological assessment, and other related services. The company recently sold its Canadian addiction treatment operations and acquired a U.S. based treatment center in Delray Beach, Florida, a major U.S. center for drug treatment programs located between Palm Beach and Miami. The company sought to expand into the U.S., where it could revolutionize treatment in that country with the skills it acquired in Canada. The company, through a subsidiary, will own and lease their assets in Canada, offering a stable secondary cash flow. Their newly acquired U.S. treatment center will be operated through a Florida limited liability company named Seastone Delray Healthcare LLC.
More than two thirds of families have been touched by a family member's addiction to alcohol, drugs, sex, and/or gambling. The addiction treatment market in the U.S. is estimated at over $35 billion annually, with a greater need than there are facilities. In addition, the GreeneStone approach differentiates itself in a number of ways:
- Residents are treated holistically, taking into consideration all factors that can feed addiction, rather than the isolated treatment of addiction alone. Upon admission, all residents are fully assessed by professionals of a multidisciplinary team to develop an overall holistic treatment plan. An assembled team of best-in-class experts, including psychiatrists, physicians, nurses, and clinicians, manage and support residents who have co-occurring disorders such as depression, anxiety, and trauma.
- Support is available both before and after resident treatment. Families can receive intervention support prior to admission, an often critical time for families and patients. Follow-up treatment support is available, to ensure progress and minimize the incidence of relapse. Families and others that are integral to the recovery are encouraged to participate in counseling and education sessions for continued success after in-patient treatment.
In addition to his experience with GreeneStone Healthcare, company president Shawn Leon has more than 25 years of experience managing public and private development-stage companies for various industries. He has provided financing and capital markets oversight for a number of these ventures, many of which have involved negotiations for mergers and acquisitions. Disclaimer
GreenStone Healthcare Corp. Company Blog
GreenStone Healthcare Corp. News:
GreeneStone Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
GreeneStone Signs Definitive Agreement to Acquire Seastone of Delray, a Florida Limited Liability Company
GreeneStone Signs LOI to Acquire Aurora Recovery
CD International Enterprises, Inc. (CDII)
The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.0155, up 14.81%, on 1,252,919 volume with 76 trades. The stock’s average daily volume over the past 60 days is 619,183 and its 52-week low/high is $0.00011/$56.00.
CD International Enterprises, Inc. (CDII) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
Through its primary website, www.CD International Enterprises, Inc., CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.
At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.
CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.
The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.
Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.
In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer
CD International Enterprises, Inc. Blog
CD International Enterprises, Inc. News:
CD International Enterprises Enters Agreement to Distribute Cannabidiol (CBD) in the United States
CD International Enterprises Enters Consulting Agreement with Zhangjianjie Shengshi Agricultural Development Company, Limited
CD International Enterprises Enters Corporation Agreement With Everbright Investment and Construction Company, Limited
InMed Pharmaceuticals, Inc. (IMLFF)
The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.40, up 11.73%, on 2,953,032 volume with 906 trades. The stock’s average daily volume over the past 60 days is 842,678, and its 52-week low/high is $0.05/$0.4261.
InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.
Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”
After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.
The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.
InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.
The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.
Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.
Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer
InMed Pharmaceuticals, Inc. Company Blog
InMed Pharmaceuticals, Inc. News:
InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media
InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media
NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use
Today's Top 3
Promotion Stock Secrets
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Bollente Companies, Inc. (BOLC) Second Generation of Trutankless® Smart Water Heaters to Be Unveiled At International Builders Show
- CD International Enterprises, Inc. (CDII) Enters Agreement to Distribute Cannabidiol, or CBD, in the United States
- ChineseInvestors.com, Inc. (CIIX) Alan Klitenic, Director of Investor Relations for ChineseInvestors.com, Discusses Recent CIIX News and Industry Trends in a New Audio Interview with SmallCapVoice.com
- Dominovas Energy Corp. (DNRG) Obtains Partner to Facilitate Financing, Development and Production for RUBICON(TM) Fuel Cell Systems
- eXp World Holdings, Inc. (EXPI) to Present at The MicroCap Conference on April 4th in New York
- GreenStone Healthcare Corp. (GRST) Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
- India Globalization Capital, Inc. (NYSE: IGC) Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders
- InMed Pharmaceuticals Inc. (IMLFF) Unique Approach Featured in Forbes -- CFN Media
- MGX Minerals Inc. (MGXMF) NetworkNewsWire Announces Publication that Reviews the Global Lithium Market and Discusses Innovators Rising to Meet Demand
- Monaker Group, Inc. (MKGI) to Present at the 29th Annual ROTH Conference, March 15, 2017
- National Waste Management Holdings, Inc. (NWMH) Expands Territory with Acquisition of Burts Refuse, LLC
- ORHub, Inc. (ORHB) NetworkNewsWire Announces Publication on Solutions for the Health Care Industry's Data Processing Needs
- ProBility Media Corp. (PBYA) Files 10Q, Reports Third Consecutive Quarter of Revenue Growth
- Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17
- Singlepoint, Inc. (SING) NetworkNewsWire Announces Publication that Highlights Marijuana Stocks and Reviews the Economic Benefits Legalization
- Stealth Technologies, Inc. (STTH) Announces 5 New Products